Tenecteplase

替奈普酶

Report date: 2026/05/26 20:00:28

Base Information

Drug NameTenecteplase
Drug Alias NameProCath替奈普酶（Genentech/Boehringer Ingelheim）特奈替普酶（Genentech/Boehringer Ingelheim）Tenecteplasum (Genentech/Boehringer Ingelheim)替尼普酶（Genentech/Boehringer Ingelheim） +[12] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionPlasminogen activators
TargetsPlasminogen
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Hemorrhagic StrokeIschemic Stroke +[20] 
Global Approved IndicationsIschemic StrokeMyocardial Infarction
Approved Indications in ChinaIschemic Stroke
Original Approved Country/TerritoryUnited States
Original Approved Date2000/06/02
Country/TerritoryBelgiumBulgariaCanada +[36] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenentech Inc
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgThe First Affiliated Hospital Of University Of Science And Technology Of ChinaXuanwu Hospital Of Capital Medical University +[16] 
Inactive CompaniesSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversityThe First Affiliated Hospital Of Zhejiang University School Of MedicineWake Forest University Health Sciences +[9] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Hemorrhagic StrokeIschemic Stroke +[16] 
Inactive IndicationsHeart ArrestCerebral InfarctionBrain Ischemia +[4] 

Other Information

ATC CodeB01AD11
Related LinksWikipediaDrugBankKEGG